Michael Powell, Director at Orexigen Therapeutics, Inc. (OREX), sold 456,254 shares at $8.76 ($3.9M) on 2010-12-17, disclosed to the SEC on 2010-12-21.
Open-market sale of $3.9M OREX by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $8.76 | 1,470 | $13K | 0.3% |
| 2 | $8.76 | 21,473 | $188K | 4.8% |
| 3 | $8.76 | 108,311 | $949K | 24.3% |
| 4 | $8.50 | 3,640 | $31K | 0.8% |
| 5 | $8.50 | 53,170 | $452K | 11.6% |
| 6 | $8.50 | 268,190 |
| $2.3M |
| 58.3% |
| Total | $8.57 avg | 456,254 | $3.9M | 100% |
| Filing → |
| OCRX | SELL | 2016-12-30 | $15K | — | Filing → |
| MIRN | BUY | 2015-10-06 | $6.0M | — | Filing → |
| AERI | SELL | 2014-07-11 | $24.2M | — | Filing → |